Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
B 9.2903 -2.00% -0.19
AFMD closed down 8.23 percent on Thursday, April 15, 2021, on 1.46 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical AFMD trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup -2.00%
Calm After Storm Range Contraction -2.00%
Upper Bollinger Band Walk Strength -2.00%
Earnings Movers Other -2.00%
Multiple of Ten Bearish Other -2.00%
Wide Bands Range Expansion -2.00%
New 52 Week Closing High Bullish -10.06%
New 52 Week High Strength -10.06%
Upper Bollinger Band Walk Strength -10.06%
Multiple of Ten Bullish Other -10.06%
Older End-of-Day Signals for AFMD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
3x Volume Pace 1 day ago
Down 10% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Affimed Therapeutics B.V. Description

Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Monoclonal Antibodies Lymphoma Prostate Cancer Blastoma Immunotherapies Glioblastoma Hematologic Malignancies Epidermal Growth Factor Receptor Head And Neck Cancer Chronic Lymphocytic Leukemia Lymphocytic Leukemia CD19 Hodgkin Lymphoma Natural Killer Cell Tumors Of The Hematopoietic And Lymphoid Tissues Non Hodgkin Lymphoma Cd30 Entospletinib

Is AFMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.78
52 Week Low 1.88
Average Volume 3,725,253
200-Day Moving Average 5.17
50-Day Moving Average 7.04
20-Day Moving Average 8.39
10-Day Moving Average 8.89
Average True Range 0.77
ADX 38.23
+DI 34.92
-DI 12.36
Chandelier Exit (Long, 3 ATRs ) 8.46
Chandelier Exit (Short, 3 ATRs ) 9.46
Upper Bollinger Band 10.15
Lower Bollinger Band 6.64
Percent B (%b) 0.81
BandWidth 41.88
MACD Line 0.75
MACD Signal Line 0.60
MACD Histogram 0.1528
Fundamentals Value
Market Cap 837.33 Million
Num Shares 88.3 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -13.22
Price-to-Sales 17.35
Price-to-Book 8.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.97
Resistance 3 (R3) 10.99 10.52 10.72
Resistance 2 (R2) 10.52 10.14 10.51 10.63
Resistance 1 (R1) 10.00 9.91 9.77 9.98 10.55
Pivot Point 9.53 9.53 9.41 9.52 9.53
Support 1 (S1) 9.01 9.15 8.78 8.99 8.41
Support 2 (S2) 8.54 8.92 8.53 8.33
Support 3 (S3) 8.02 8.54 8.24
Support 4 (S4) 8.00